Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisdexamfetamine for freezing of gait in Parkinson's disease
IRCT20251122068081N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Parkinson's disease (PD) comparing Lisdexamfetamine with Placebo (2 arms). Primary endpoints: Change in freezing of gait severity and Freezing of Gait questionnaire score. Started Dec 2025; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on IRCT20251122068081N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251122068081N1.